Dr. Tendulkar Discusses Post-Prostatectomy Radiation Therapy

Video

In Partnership With:

Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

In a study on monitoring prostate-specific antigen (PSA) levels, it was revealed that men who had radical prostatectomy with high-risk features will have recurrence up to 50% post-op. Tendulkar observed that as the PSA goes up, the risk of mortality also goes up.

Patients at higher risk for PSA recurrence are those with a high Gleason score, as well as those that have positive margins. Monitoring these patients closely after surgery is key, says Tendulkar, as it helps physicians refer the patient to the appropriate radiation oncologist to go over treatment options.

Earlier intervention, side effect management, and careful monitoring by blood test have been shown to make a difference in detecting recurrence.

The key finding from this study is that there is a varying spectrum of prostate cancer, with some patients that require very aggressive treatment, so this is an important step in individualizing that treatment.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD